If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Share News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Caparo raises £50.2m in AIM float

Tue, 12th Oct 2010 17:52
India-focused wind power generation investor Caparo Energy has joined AIM today after a £50.2m fund raising. The net proceeds of the placing at 115p a share were £46.3m. The cash will be spent on purchasing existing projects from Suzlon Energy and to provide working capital. The acquisition of further generating capacity will be funded by a combination of equity and debt. Caparo has already secured outline terms of a $101.9m lending facility from IDFC. Suzlon has granted Caparo first refusal over its projects between 50MW and 100MW in size. Suzlon will deliver up to 3,000MW of projects. In return, Suzlon will receive advances totalling up to $167.9m from Caparo Energy, payable in four instalments over a period of three years.The strategy is to acquire and develop 5,000MW of generating capacity by 2017. Caparo hopes to have taken on 3,000MW of Suzlon projects by 2016 and the rest by the following year. Indian generation capacity of 163GW is not sufficient to maintain the present level of growth and there are already blackouts. The Indian government is targeting a capacity of 342GW by 2017. Favourable tariffs, incentives and Renewable Energy Certificates, mean that the market is skewed towards wind farms. By 2030, 15% of power needs are expected to come from wind. India needs a slightly different technology to Europe because the wind speed tends to be lower.Caparo ended the first day's trading at 115.25p a share, which values the company at £188.59m. Caparo says that it will consider paying a dividend when it has developed at least 500MW of capacity.

Related News

IN BRIEF: Celadon to seek approval for de-listing from London's AIM
2 Jul 2025

IN BRIEF: Celadon to seek approval for de-listing from London's AIM

Celadon Pharmaceuticals PLC - London-based pharmaceutical company which grows medical cannabis for the chronic pain market - Intends to seek sharehold...

Celadon proposes delisting, re-registration as private company
2 Jul 2025

Celadon proposes delisting, re-registration as private company

(Sharecast News) - Celadon Pharmaceuticals announced on Wednesday that it intends to delist its shares from AIM and re-register as a private limited c...

Celadon Pharmaceuticals News

IN BRIEF: Celadon to seek approval for de-listing from London's AIM
2 Jul 2025

IN BRIEF: Celadon to seek approval for de-listing from London's AIM

Celadon Pharmaceuticals PLC - London-based pharmaceutical company which grows medical cannabis for the chronic pain market - Intends to seek sharehold...

Celadon proposes delisting, re-registration as private company
2 Jul 2025

Celadon proposes delisting, re-registration as private company

(Sharecast News) - Celadon Pharmaceuticals announced on Wednesday that it intends to delist its shares from AIM and re-register as a private limited c...

AIM WINNERS & LOSERS: MediaZest swings to profit, remains optimistic
30 Jun 2025

AIM WINNERS & LOSERS: MediaZest swings to profit, remains optimistic

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.

Celadon evades administration with new loan amid plans to delist
11 Jun 2025

Celadon evades administration with new loan amid plans to delist

(Alliance News) - Celadon Pharmaceuticals PLC on Wednesday said it had received GBP500,000 in funding from an anonymous lender.

AIM WINNERS & LOSERS: Celadon jumps; Frasers eyes Revolution Beauty
9 Jun 2025

AIM WINNERS & LOSERS: Celadon jumps; Frasers eyes Revolution Beauty

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.

Celadon Pharmaceuticals still facing cash crisis
30 Apr 2025

Celadon Pharmaceuticals still facing cash crisis

(Sharecast News) - Celadon Pharmaceuticals reiterated on Wednesday that it has yet to receive funds under its secured credit facility, and was still f...